In January and February 2026, the Company issued 3,162,785 shares of common stock with the aggregate gross purchase price of $7,264 under Advance Notices to YA in accordance with the terms of the SEPA.

In January 2026, the Company entered into a loan agreement with its Chief Executive Officer and Chairman for an unsecured loan in the principal amount of $147 to fund the premium for the Company’s directors’ and officers’ liability insurance. The loan had a nine-month term from the date of advance and may be prepaid at any time without penalty. No interest accrued during the first three months following funding; thereafter, the outstanding principal bore interest at a variable rate equal to three-month Term SOFR plus 2.0% per annum, with any accrued interest payable at maturity or upon earlier repayment. The loan was not secured by any collateral and is not guaranteed by any third party.

On February 18, 2026, the Company received written notification from the Panel of the Nasdaq Stock Market stating that, due to the Company not having met the terms of the Panel’s November 10, 2025 decision that the Company demonstrate compliance with the minimum equity standard requirement under Nasdaq Listing Rule 5550(b)(1) by February 16, 2026, the Company’s securities would be delisted from Nasdaq, and trading was suspended at the open of trading on February 23, 2026. The Company was provided fifteen (15) days from receipt of the aforementioned notice of the Panel’s decision to request that the Nasdaq Listing and Hearing Review Council (the “Council”) review the decision.

Effective February 23, 2026, the Company’s Common Stock was delisted from The Nasdaq Capital Market following the Company’s non-compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement). The Company’s Common Stock is now quoted on the OTC Pink Limited Market under the ticker symbol “ABPO.” The delisting does not affect the Company’s operations, but may have, among other material adverse effects, an adverse impact on the liquidity and market price of the Common Stock and on the Company’s ability to raise capital and on favorable terms, if at all, in the future.

On March 18, 2026, the Company formally appealed the delisting determination and is expecting the response in April 2026.